About Wegovy Weight Loss: What It Actually Does (and What It Doesn't)

The myth that Wegovy is a shortcut (and why that framing gets the biology backwards

The most common misconception our prescribers encounter is that semaglutide somehow bypasses the need for lifestyle changes) that you inject once a week and the weight takes care of itself. The reality is almost the opposite. Wegovy is licensed alongside a reduced-calorie diet and increased physical activity, not instead of them. What it actually does is shift the hormonal environment that makes those changes so difficult. Semaglutide activates GLP-1 receptors in the gut and brain, suppressing appetite signals and slowing gastric emptying so that food sits in the stomach longer. People on treatment often describe genuinely feeling full after smaller meals, not choosing to eat less through willpower, but simply not being as hungry. That distinction matters enormously for understanding what this medicine is and isn't. It addresses the biology of weight regulation, which research increasingly shows is driven by hormones and brain signalling, not personal resolve. If you'd like to read more about how semaglutide works as a medicine before anything else, our tell me about Wegovy page is a good place to start, or if you want a broader overview, our dedicated page on Wegovy for weight loss covers the full picture from treatment goals to realistic outcomes. The NHS also has a clear patient-level explanation on the NHS semaglutide medicines page. Weight loss on Wegovy is real; it's just not passive.

What the trial evidence actually says, and where the 15% figure comes from

The headline number you'll see attached to Wegovy is roughly 15% average body-weight reduction. That comes from the STEP 1 trial: 68 weeks, 2.4mg semaglutide, adults with obesity or overweight plus at least one weight-related condition but without type 2 diabetes, compared against placebo alongside lifestyle support. The published results in the New England Journal of Medicine are one of the strongest datasets in weight-management medicine. What the headline doesn't tell you is that individual results spread across a wide range, some participants lost considerably more, others less. The average is a useful benchmark, not a personal forecast. A more recent development raised the ceiling further: the MHRA approved a 7.2mg semaglutide pen in April 2026, with trial data reporting around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest dose. For anyone specifically researching what drives Wegovy weight loss and how those results are achieved in practice, we have a dedicated page that covers the topic in detail. The short version: the evidence is substantial and peer-reviewed, and the results are meaningful, hedged, as they should be, because your outcome depends on your biology, your dose, and how consistently you engage with treatment.

Who Wegovy is actually licensed for in the UK, and what NICE says about NHS access

Privately, the licensed eligibility criteria follow the Wegovy SmPC: adults aged 18 and over with a BMI of 30 or higher, or 27 or higher if there is at least one weight-related condition such as high blood pressure, high cholesterol, pre-diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Meeting those numbers doesn't guarantee a prescription, a prescriber weighs your full medical history, any contraindications, and your individual circumstances. On the NHS, access runs through specialist weight management services under NICE guidance (TA875), which sets stricter criteria including a maximum treatment duration of two years and a requirement for multidisciplinary support. Waiting lists for NHS specialist services are often long. For context on what private treatment costs and what's included, the Wegovy cost in the UK page covers that honestly. Worth knowing: Wegovy also carries a Black Triangle designation (▼), meaning the MHRA requires additional monitoring of this medicine while post-market safety data continues to build. That's standard for newer medicines, not a red flag, but it does mean your prescriber reviews your progress at every repeat, which is how it should work. Our clinical team takes that review process seriously.

Side effects, the second week, and when to seek help

The side-effect profile of Wegovy is led by the gut. Nausea is the most commonly reported effect, particularly in the early weeks or after a dose increase. Vomiting, diarrhoea, constipation and indigestion are also common. For most people these are mild to moderate and settle as the body adjusts, often within a couple of weeks of starting or stepping up. The titration schedule exists precisely to give your system time to adapt. A question the team hears regularly is whether the second week feels harder than the first; if you're navigating that, this page on the second week of Wegovy addresses it directly. Less commonly, more serious effects can occur. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines: severe or persistent stomach pain, especially if it radiates to the back, warrants urgent medical attention. You can report any suspected side effect through the MHRA Yellow Card scheme. Wegovy is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. If any of those situations apply to you, speak with your GP before starting or continuing treatment. One practical note: if you're thinking about starting and payday or a bank holiday means your first order would land mid-week, orders placed before 12pm on any working day are dispatched the same day once approved, so timing is more flexible than it might seem.